Comparative Pharmacology
Head-to-head clinical analysis: CARDENE versus CLEVIPREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE versus CLEVIPREX.
CARDENE vs CLEVIPREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
Cleviprex (clevidipine) is a dihydropyridine L-type calcium channel blocker with high vascular selectivity. It inhibits calcium influx into vascular smooth muscle cells, causing arterial vasodilation and reduced peripheral vascular resistance.
20-40 mg orally three times daily.
Initiate intravenous infusion at 1-2 mg/kg/hr, titrate by 0.5-1 mg/kg/hr every 90 minutes up to maximum 32 mg/kg/hr. Maintenance dose: 4-6 mg/kg/hr. Route: IV. Frequency: continuous infusion.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Terminal elimination half-life: 2.7 minutes (dihydropyridine ring reduction) and 15 minutes (ester hydrolysis); clinical context: rapid offset allows precise titration
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Renal: 63–73% as metabolites, fecal: 7–10%, unchanged drug in urine: <1%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker